Preference of Genetic Polymorphism and Pharmacokinetics

Preference of CYP450 2B6 516 G>T Polymorphism and Pharmacokinetics of Plasma Efavirenz in A Group of HIV Infected Southern Chinese

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01658371

Enrollment

100

Registered

2012-08-07

Start date

2008-05-31

Completion date

2010-06-30

Last updated

2012-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV

Keywords

HIV

Brief summary

Genetic polymorphism affects plasma concentration of antiretroviral therapy in HIV patients. The investigators investigate the prevalence of genetic polymorphism affecting efavirenz metabolism and the corresponding pharmacokinetics of different genotypes.

Detailed description

Eligible patients are invited to donate blood samples for pharmacokinetic study and genotype analysis

Interventions

None listed

Study design

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Southern Chinese HIV patients on efavirenz

Exclusion criteria

* Refuse to sign consent, HIV patients not on efavirenz

Design outcomes

Primary

Measure	Time frame	Description
pharmacokinetics	24 hour	This includes plasma concentration of drugs in relation to time, in different genotypes

Secondary

Measure	Time frame
genotypes frequency	1 year

Countries

China

Outcome results